MabLab develops self-administered rapid tests utilizing monoclonal antibody technology to detect five lethal lacing agents in drugs and drinks, providing results in under three minutes. This solution aims to prevent over 100,000 overdose deaths and five million hospitalizations annually by alerting users to dangerous additives.
Funding
Funding not disclosed
Founders
Product
Problem
The increasing prevalence of drug overdoses, with over 100,000 deaths annually, is often attributed to the presence of lethal lacing agents in drugs and drinks. Current methods for detecting these substances are often slow, expensive, and not readily accessible to the general public, hindering timely intervention and preventative measures. This lack of immediate detection tools contributes to preventable hospitalizations and fatalities.
Solution
MabLab provides rapid, self-administered test strips for detecting five common and lethal drug-lacing agents in both drugs and drinks. Utilizing monoclonal antibody technology, the test delivers accurate results in under three minutes, enabling users to quickly identify the presence of dangerous additives. By offering an affordable and easy-to-use solution, MabLab aims to reduce overdose deaths and hospitalizations by providing individuals with the means to screen substances before consumption. The test strips require mixing a sample with a provided buffer solution to reveal results in seconds.
Target Audience
The primary target audience includes individuals who use drugs or consume drinks in environments where lacing is a concern, as well as harm reduction organizations, event venues, and healthcare providers seeking to prevent overdoses.
Features
- Rapid detection of five lethal lacing agents in under three minutes.
- Utilizes monoclonal antibody technology for accurate results.
- Self-administered test requiring no specialized equipment.
- Affordable and accessible for widespread use.
- Easy-to-use format involving mixing a sample with a buffer solution.